Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MaxCyte has agreed to license its cell loading system to Sangamo BioSciences for use in its ZFP therapeutic HIV research program.
Subscribe to our email newsletter
The two companies have initiated an R&D plan to evaluate and further develop the GMP-compliant MaxCyte system to load zinc finger DNA-binding protein (ZFP)-based therapeutics into cells. Sangamo also has the option to utilize MaxCyte’s system for ZFP Therapeutics in oncology.
The agreement provides Sangamo an option for a commercial license to MaxCyte’s technology that includes a supply contract and clinical and commercial milestones to MaxCyte for products developed under the agreement. Financial terms of the agreement were not disclosed.
“Preclinical data employing Sangamo’s ZFN approach are encouraging, and we are excited about working with Sangamo to help move its HIV product into clinical trials. We’re confident that the unmatched efficiency and scalability of our cell loading technology can have a positive impact on the clinical and commercial production of promising therapeutics such as Sangamo’s,” said Douglas Doerfler, president and CEO of MaxCyte.